急性汎発性発疹性膿疱症 (Japanese Wikipedia)

Analysis of information sources in references of the Wikipedia article "急性汎発性発疹性膿疱症" in Japanese language version.

refsWebsite

Global rank Japanese rank

4^th place

24^th place

2^nd place

6^th place

low place

1,159^th place

5^th place

19^th place

7,563^rd place

low place

dermnetnz.org

“Acute generalised exanthematous pustulosis | DermNet NZ” (英語). dermnetnz.org. 2021年1月14日閲覧。

doi.org

“Adverse cutaneous drug eruptions: current understanding”. Seminars in Immunopathology 38 (1): 75–86. (2016). doi:10.1007/s00281-015-0540-2. PMID 26553194.
“Acute generalized exanthematous pustulosis: clinical characteristics, etiologic associations, treatments, and outcomes in a series of 28 patients at Mayo Clinic, 1996-2013”. International Journal of Dermatology 56 (4): 405–414. (2017). doi:10.1111/ijd.13434. PMID 28084022.
Halevy S (August 2009). “Acute generalized exanthematous pustulosis”. Curr Opin Allergy Clin Immunol 9 (4): 322–8. doi:10.1097/ACI.0b013e32832cf64e. PMID 19458527.
“Pharmacogenomics of off-target adverse drug reactions”. British Journal of Clinical Pharmacology 83 (9): 1896–1911. (2017). doi:10.1111/bcp.13294. PMC 5555876. PMID 28345177.
“Acute Generalized Exanthematous Pustulosis: Pathogenesis, Genetic Background, Clinical Variants and Therapy”. International Journal of Molecular Sciences 17 (8): 1214. (July 2016). doi:10.3390/ijms17081214. PMC 5000612. PMID 27472323.
“Severe cutaneous adverse reactions to drugs”. Lancet 390 (10106): 1996–2011. (2017). doi:10.1016/S0140-6736(16)30378-6. PMID 28476287.
“Five-Year Retrospective Review of Acute Generalized Exanthematous Pustulosis”. Dermatology Research and Practice 2015: 260928. (2015). doi:10.1155/2015/260928. PMC 4689982. PMID 26783390.
“Acute generalized exanthematous pustulosis (AGEP): A review and update”. Journal of the American Academy of Dermatology 73 (5): 843–8. (November 2015). doi:10.1016/j.jaad.2015.07.017. PMID 26354880.
“Clinicopathologic manifestations of 36 Korean patients with acute generalized exanthematous pustulosis: a case series and review of the literature”. Annals of Dermatology 22 (2): 163–9. (May 2010). doi:10.5021/ad.2010.22.2.163. PMC 2883418. PMID 20548906.
Ropars, Nolwenn; Darrieux, Laure; Tisseau, Laurent; Safa, Gilles (2014-09-28). “Acute generalized exanthematous pustulosis associated with primary Epstein-Barr virus infection”. JAAD Case Reports 1 (1): 9–11. doi:10.1016/j.jdcr.2014.09.004. ISSN 2352-5126. PMC 4802527. PMID 27075126.
“Current Perspectives on Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis”. Clinical Reviews in Allergy & Immunology 54 (1): 147–176. (February 2018). doi:10.1007/s12016-017-8654-z. PMID 29188475.
“Classification of Drug Hypersensitivity into Allergic, p-i, and Pseudo-Allergic Forms”. International Archives of Allergy and Immunology 171 (3–4): 166–179. (2016). doi:10.1159/000453265. PMID 27960170.
“Immunopathogenesis and risk factors for allopurinol severe cutaneous adverse reactions”. Current Opinion in Allergy and Clinical Immunology 16 (4): 339–45. (2016). doi:10.1097/ACI.0000000000000286. PMID 27362322.
“Recent advances in the understanding of severe cutaneous adverse reactions”. The British Journal of Dermatology 177 (5): 1234–1247. (November 2017). doi:10.1111/bjd.15423. PMC 5582023. PMID 28256714.
“Pustular psoriasis and related pustular skin diseases”. The British Journal of Dermatology 178 (3): 614–618. (January 2018). doi:10.1111/bjd.16232. PMID 29333670.
“Immunohistopathological Findings of Severe Cutaneous Adverse Drug Reactions”. Journal of Immunology Research 2017: 6928363. (2017). doi:10.1155/2017/6928363. PMC 5684554. PMID 29226159.

nih.gov

pubmed.ncbi.nlm.nih.gov

“Adverse cutaneous drug eruptions: current understanding”. Seminars in Immunopathology 38 (1): 75–86. (2016). doi:10.1007/s00281-015-0540-2. PMID 26553194.
“Acute generalized exanthematous pustulosis: clinical characteristics, etiologic associations, treatments, and outcomes in a series of 28 patients at Mayo Clinic, 1996-2013”. International Journal of Dermatology 56 (4): 405–414. (2017). doi:10.1111/ijd.13434. PMID 28084022.
Halevy S (August 2009). “Acute generalized exanthematous pustulosis”. Curr Opin Allergy Clin Immunol 9 (4): 322–8. doi:10.1097/ACI.0b013e32832cf64e. PMID 19458527.
“Pharmacogenomics of off-target adverse drug reactions”. British Journal of Clinical Pharmacology 83 (9): 1896–1911. (2017). doi:10.1111/bcp.13294. PMC 5555876. PMID 28345177.
“Acute Generalized Exanthematous Pustulosis: Pathogenesis, Genetic Background, Clinical Variants and Therapy”. International Journal of Molecular Sciences 17 (8): 1214. (July 2016). doi:10.3390/ijms17081214. PMC 5000612. PMID 27472323.
“Severe cutaneous adverse reactions to drugs”. Lancet 390 (10106): 1996–2011. (2017). doi:10.1016/S0140-6736(16)30378-6. PMID 28476287.
“Five-Year Retrospective Review of Acute Generalized Exanthematous Pustulosis”. Dermatology Research and Practice 2015: 260928. (2015). doi:10.1155/2015/260928. PMC 4689982. PMID 26783390.
“Acute generalized exanthematous pustulosis (AGEP): A review and update”. Journal of the American Academy of Dermatology 73 (5): 843–8. (November 2015). doi:10.1016/j.jaad.2015.07.017. PMID 26354880.
“Clinicopathologic manifestations of 36 Korean patients with acute generalized exanthematous pustulosis: a case series and review of the literature”. Annals of Dermatology 22 (2): 163–9. (May 2010). doi:10.5021/ad.2010.22.2.163. PMC 2883418. PMID 20548906.
Ropars, Nolwenn; Darrieux, Laure; Tisseau, Laurent; Safa, Gilles (2014-09-28). “Acute generalized exanthematous pustulosis associated with primary Epstein-Barr virus infection”. JAAD Case Reports 1 (1): 9–11. doi:10.1016/j.jdcr.2014.09.004. ISSN 2352-5126. PMC 4802527. PMID 27075126.
“Current Perspectives on Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis”. Clinical Reviews in Allergy & Immunology 54 (1): 147–176. (February 2018). doi:10.1007/s12016-017-8654-z. PMID 29188475.
“Classification of Drug Hypersensitivity into Allergic, p-i, and Pseudo-Allergic Forms”. International Archives of Allergy and Immunology 171 (3–4): 166–179. (2016). doi:10.1159/000453265. PMID 27960170.
“Immunopathogenesis and risk factors for allopurinol severe cutaneous adverse reactions”. Current Opinion in Allergy and Clinical Immunology 16 (4): 339–45. (2016). doi:10.1097/ACI.0000000000000286. PMID 27362322.
“Recent advances in the understanding of severe cutaneous adverse reactions”. The British Journal of Dermatology 177 (5): 1234–1247. (November 2017). doi:10.1111/bjd.15423. PMC 5582023. PMID 28256714.
“Pustular psoriasis and related pustular skin diseases”. The British Journal of Dermatology 178 (3): 614–618. (January 2018). doi:10.1111/bjd.16232. PMID 29333670.
“Immunohistopathological Findings of Severe Cutaneous Adverse Drug Reactions”. Journal of Immunology Research 2017: 6928363. (2017). doi:10.1155/2017/6928363. PMC 5684554. PMID 29226159.

ncbi.nlm.nih.gov

pmc.ncbi.nlm.nih.gov

dailymed.nlm.nih.gov

“HYDROXYZINE HYDROCHLORIDE tablet”. Daily Med. U.S. National Library of Medicine. 25 October 2020閲覧。

nihs.go.jp

“医薬品安全性情報Vol.10 No.15（2012/07/19）”. 国立医薬品食品衛生研究所. 2021年6月16日閲覧。

worldcat.org

search.worldcat.org

Ropars, Nolwenn; Darrieux, Laure; Tisseau, Laurent; Safa, Gilles (2014-09-28). “Acute generalized exanthematous pustulosis associated with primary Epstein-Barr virus infection”. JAAD Case Reports 1 (1): 9–11. doi:10.1016/j.jdcr.2014.09.004. ISSN 2352-5126. PMC 4802527. PMID 27075126.